Back to discover
Disease
Hyperphosphatemia
Late-stage therapeutic developmentEmerging research
1
Publications
18
Clinical trials
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Research2024-01-11Arteriosclerosis, thrombosis, and vascular biology
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 4 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
- Q4 2026A Phase 3, Randomized, Placebo-controlled, Double-blind, Phosphate Binder-combination Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
- Q1 2027A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Serum Phosphate Lowering Effect of Fixed Dose AP306 in Participants With Hyperphosphatemia Receiving Maintenance Hemodialysis
- Q2 2027An Open-label, Single-arm Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis
- Q3 2027A Phase 3 Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
Major developments
Upcoming trial readoutHigh impact
Results expected Q2 20272026-06-10
Upcoming trial readoutHigh impact
Results expected Q4 20262026-04-17
Clinical MilestonesViewHide
Results expected
- 2026-06-29A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Serum Phosphate Lowering Effect of Fixed Dose AP306 in Participants With Hyperphosphatemia Receiving Maintenance HemodialysisResults expected Q1 2027
- 2026-06-10An Open-label, Single-arm Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal DialysisResults expected Q2 2027
- 2026-04-17A Phase 3, Randomized, Placebo-controlled, Double-blind, Phosphate Binder-combination Study of TS-172 in Hyperphosphatemia Patients on HemodialysisResults expected Q4 2026
- 2025-12-16A Phase 3 Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate BindersResults expected Q3 2027
Recently completed
- 2026-06-20A Randomized, Double-Blind, Multi-Regional, Phase 3 Study to Evaluate the Efficacy and Safety of AP301 on Serum Phosphorus Control in Chronic Kidney Disease Patients Receiving Maintenance Dialysis With HyperphosphatemiaPrimary completion
- 2025-10-20A Phase 3, Randomized, Placebo-controlled, Double-blind Study of TS-172 in Hyperphosphatemia Patients on HemodialysisCompleted
Activity timeline6
- 2026-06-29ClinicalA Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Serum Phosphate Lowering Effect of Fixed Dose AP306 in Participants With Hyperphosphatemia Receiving Maintenance HemodialysisResults expected Q1 2027
- 2026-06-20ClinicalA Randomized, Double-Blind, Multi-Regional, Phase 3 Study to Evaluate the Efficacy and Safety of AP301 on Serum Phosphorus Control in Chronic Kidney Disease Patients Receiving Maintenance Dialysis With HyperphosphatemiaPrimary completion
- 2026-06-10ClinicalAn Open-label, Single-arm Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal DialysisResults expected Q2 2027
- 2026-04-17ClinicalA Phase 3, Randomized, Placebo-controlled, Double-blind, Phosphate Binder-combination Study of TS-172 in Hyperphosphatemia Patients on HemodialysisResults expected Q4 2026
- 2025-12-16ClinicalA Phase 3 Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate BindersResults expected Q3 2027
- 2025-10-20ClinicalA Phase 3, Randomized, Placebo-controlled, Double-blind Study of TS-172 in Hyperphosphatemia Patients on HemodialysisCompleted
Clinical trials
The current development programme across all trial phases.
Clinical programme
18
6
15
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Major themes4
- Cardiovascular Diseases1
- Hyperphosphatemia1
- Renal Insufficiency, Chronic1
- Vascular Calcification1
Leading journals1
- Arteriosclerosis, thrombosis, and vascular biology1
Leading researchers8
- Aikawa E1
- Beck L1
- Chen Y1
- Hill Gallant KM1
- Kuro-O M1
- Moe OW1
- Moe SM1
- Turner ME1
Affiliations (unnormalised)6
- Center for Excellence in Vascular Biology (E.A.)1
- Center for Interdisciplinary Cardiovascular Sciences (M.E.T.1
- Center for Molecular Medicine1
- Charles and Jane Pak Center for Mineral Metabolism and Clinical Research (O.W.M.)1
- Indiana University School of Medicine1
- Nantes Université1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.